特點(diǎn) Feature | 說明 Description | 客戶價值 Value |
Dual T2DM & Obesity Action 雙重降糖減重作用 | Potent GLP-1 receptor agonist delivering robust HbA1c reduction (up to 1.5-2.0%) and clinically meaningful weight loss (10-15% body weight). 強(qiáng)效GLP-1受體激動劑，提供顯著的糖化血紅蛋白降低（高達(dá)1.5-2.0%）和具有臨床意義的體重減輕（10-15%體重）。 | Addresses the largest and fastest-growing metabolic therapeutic market with dual revenue streams from diabetes and obesity indications. 瞄準(zhǔn)最大且增長最快的代謝治療市場，從糖尿病和肥胖適應(yīng)癥獲得雙重收入來源。 |
Once-Weekly Convenience 每周一次便捷性 | Fatty acid acylation technology enables albumin binding with plasma half-life of ~5-7 days, supporting weekly dosing. 脂肪酸酰化技術(shù)實(shí)現(xiàn)白蛋白結(jié)合，血漿半衰期約5-7天，支持每周給藥。 | Superior patient adherence versus daily alternatives; aligns with current standard-of-care expectations in the GLP-1 market. 與每日給藥替代品相比患者依從性更優(yōu)；符合GLP-1市場中當(dāng)前的護(hù)理標(biāo)準(zhǔn)期望。 |
Cardiovascular Benefit Potential 心血管獲益潛力 | Emerging clinical data suggests significant reduction in MACE endpoints consistent with established GLP-1 agonist class effects. 新興臨床數(shù)據(jù)顯示主要不良心血管事件（MACE）終點(diǎn)顯著降低，與已確立的GLP-1激動劑類效應(yīng)一致。 | CV outcome differentiation increasingly determines payer coverage and market access; strong competitive positioning. 心血管結(jié)局差異化越來越?jīng)Q定支付方覆蓋和市場準(zhǔn)入；具有強(qiáng)競爭定位。 |
Engineered Molecular Design 工程化分子設(shè)計(jì) | Optimized peptide backbone with site-specific acylation for enhanced albumin affinity and reduced immunogenicity. 優(yōu)化的肽骨架，通過位點(diǎn)特異性?；鰪?qiáng)白蛋白親和力并降低免疫原性。 | Advanced molecular architecture provides improved stability and consistent pharmacokinetics across patient populations. 先進(jìn)的分子結(jié)構(gòu)在所有患者群體中提供改進(jìn)的穩(wěn)定性和一致的藥代動力學(xué)。 |
Explosive Market Growth 市場爆發(fā)式增長 | The global GLP-1 agonist market is projected to exceed $50 billion by 2030, driven by obesity indication expansion. 全球GLP-1激動劑市場預(yù)計(jì)到2030年將超過500億美元，由肥胖適應(yīng)癥擴(kuò)展驅(qū)動。 | High-volume API demand from generic developers and emerging market manufacturers creates premium supply opportunities. 仿制藥開發(fā)商和新興市場制造商的高容量API需求創(chuàng)造優(yōu)質(zhì)供應(yīng)機(jī)會。 |
Scalable GMP Manufacturing 可擴(kuò)展GMP生產(chǎn) | Multi-kilogram GMP manufacturing capacity with validated processes, full stability programs, and global regulatory documentation. 多公斤GMP生產(chǎn)能力，具有經(jīng)驗(yàn)證的生產(chǎn)工藝、完整的穩(wěn)定性項(xiàng)目和全球法規(guī)文件。 | Reliable commercial supply for Phase III through launch, with batch records suitable for US FDA, EMA, and NMPA filings. 從III期到上市的可靠商業(yè)供應(yīng)，批記錄適用于美國FDA、EMA和NMPA申報(bào)。 |
Full-Service API Partner 全服務(wù)API合作伙伴 | Integrated supply of Ecnoglutide API, reference standards, potency assays, and complete regulatory submission dossiers. 受體激動劑API、對照品、效價測定和完整法規(guī)申報(bào)文件的集成供應(yīng)。 | End-to-end procurement simplifies supply chain management and accelerates time-to-market for formulation partners worldwide. 端到端采購簡化供應(yīng)鏈管理，加速全球制劑合作伙伴的上市時間。 |